Close Menu

NEW YORK (360Dx) – RPRD Diagnostics today announced it and Orient Bio have inked a memorandum of understanding that will expand the availability of RPRD's pharmacogenomic testing services to South Korea.

Additionally, Orient Bio will diversify its business to include new areas, including precision medicine and clinical PGx, said RPRD, which stands for Right Patient Right Drug.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.

Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.

NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.

In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.